Device Trial Radar · NCT05241665
First in Human Study
Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jul 28, 2022
Primary completion
Apr 21, 2023
Study completion May 21, 2023
Sponsor
- Lead sponsor
- SpectraWAVE, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 16, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigational, prospective, multi-site, first in human, feasibility evaluation
Conditions
- Coronary Artery Disease
Interventions
SpectraWAVE Imaging SystemDevice
Coronary imaging
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility EvaluationTime frame: From informed consent to hospital discharge after the SpectraWAVE Imaging System procedure, an average of less than one day.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Angiografia De Occidente S.A
Cali, Colombia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.